drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
An autologous dual-target CAR T-cell therapy engineered to express chimeric antigen receptors against BCMA and CD19; patient T cells are collected, modified ex vivo, and reinfused after lymphodepletion to eliminate BCMA+/CD19+ clonal plasma and B cells in relapsed/refractory systemic AL amyloidosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express dual chimeric antigen receptors targeting BCMA and CD19. After lymphodepletion, the cells are reinfused to recognize and kill BCMA+ plasma cells and CD19+ B-lineage cells via CAR-mediated activation, degranulation (perforin/granzyme), and cytokine release, aiming to eliminate clonal cells that produce amyloidogenic light chains in systemic AL amyloidosis.
drug_name
FKC288
nct_id_drug_ref
NCT05978661